Quantcast

Latest Eva Feldman Stories

2014-08-08 08:25:57

GERMANTOWN, Md., Aug. 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a business and clinical update. "We are pleased to report that 2014 has already seen the company achieve several major milestones. In late July, we completed the last of the surgeries in the NSI-566/ALS Phase II trial. Each of the patients in the final cohort have received a total of 16 million NSI-566 neural...

2014-08-04 08:29:33

GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The multicenter Phase II trial treated 15 ambulatory patients in five different dosing cohorts. The first 12 patients received injections in the cervical region of the spinal cord only, where the stem cells...

2014-06-04 08:30:08

ANN ARBOR, Mich., June 4, 2014 /PRNewswire-USNewswire/ -- A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School. Carl June, M.D. of the Perelman School of Medicine at the University of Pennsylvania will receive the $100,000 prize in...

2014-05-12 08:33:28

ROCKVILLE, Md., May 12, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and clinical update. "During the first quarter of 2014, we continued to advance the NSI-566 cell therapy platform through human clinical trials. We have completed treatment of the fourth cohort in our ALS Phase II escalating dose trials, in collaboration with our sites at University of Michigan, Emory and...

2014-04-29 12:28:31

ANN ARBOR, Mich., April 29, 2014 /PRNewswire-USNewswire/ -- Some virtuosos express their talents through clay, paint, wood, words or dance. For others, the media are the very cells and molecules of the human body. Each expert excels in his or her chosen field, and on one unprecedented night in May, they will come together in Detroit for a gala celebration: An Evening of Art + Science. This unique fundraising event will unveil the works inspired by the pairing of 11...

2014-04-07 08:32:26

Will Also Present Update on Ongoing Phase II Trial ROCKVILLE, Md., April 7, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) will present Phase I data at the Keystone Symposia, "Engineering Cell Fate and Function," in Olympic Valley, California, on April 9(th...

2014-03-17 08:28:00

ROCKVILLE, Md., March 17, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full. In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial...

2014-03-10 08:31:05

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "2013 was an exciting year for advancement in our NSI-566 cell therapy clinical programs," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "Our Phase II ALS trial...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related